Saba Labs, a startup licensing technology from Samford University, secures $2m over two separate rounds for chronic wounds medtech.

Life sciences startup Saba Labs has secured $2m in two separate rounds to further develop its chronic wounds technology.

Saba did not reveal the investors, nor the actual size of the two different rounds.

The company, founded in April, has licensed technology from Samford University. Based on Egyptian Privet, a plant used by the Romans to dress wounds, the company has developed a spray to promote tissue regeneration.

According to Saba Labs’ CEO Philip White, early clinical trials have demonstrated strong results, and the firm will now be pursuing approval from the Food and Drug Administration.

White added: “Our product can be used for surgical site infections and chronic wounds that have problems healing or are infected. It creates a barrier, keeps the wound moist, and prevents other microorganisms from attacking the wounds.”